Amneal Launches Lanreotide Injection After FDA Approval, Targeting $983M Market
Event summary
- Amneal Pharmaceuticals received FDA approval for its lanreotide injection, a generic version of Ipsen's SOMATULINE® Depot.
- The product launched immediately with in-house manufacturing support, receiving Competitive Generic Therapy (CGT) designation.
- Lanreotide is indicated for acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome.
- U.S. annual sales for the reference product were $983 million for the 12 months ended July 2026, per IQVIA.
The big picture
Amneal's FDA approval and immediate launch of lanreotide injection expand its complex injectables portfolio, a strategic move in the competitive generics space. The CGT designation and in-house manufacturing capabilities position Amneal to challenge Ipsen's dominance in the $983M market, reflecting broader industry trends toward affordable oncology treatments. This approval strengthens Amneal's Affordable Medicines segment, which spans retail generics, injectables, and biosimilars.
What we're watching
- Market Penetration
- How Amneal will leverage its in-house manufacturing to capture share in the $983M lanreotide market.
- Competitive Dynamics
- Whether Amneal can sustain pricing pressure against Ipsen's branded SOMATULINE® Depot.
- Portfolio Expansion
- The pace at which Amneal integrates lanreotide into its broader complex injectables portfolio.
Related topics